In the February issue of Cancer Immunology Research [8], Jhaveri and colleagues used quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer patients treated with allogeneic, granulocyte-macrophage colony stimulating factor-secreting pancreatic cancer vaccine (GVAX). Here, CSF2 is linked to familial pancreatic carcinoma.